Phase I/II Clinical Study to Evaluate VB15010 Tablets in Patients With Advanced Solid Tumors
About this study
This research is designed to determine if experimental treatment with PARP1 inhibitor, VB15010 is safe, tolerable, and has anti-cancer activity in patients with advanced solid tumors.
- Condition
- Cancer, Neoplasms, Neoplasms, Breast, Tumor, PARP, Ovarian Neoplasms, Prostatic Cancer, Pancreatic Cancer, Breast Cancer, Biliary Cancer, Colorectal Cancer
- Tested
- VB15010
- Sponsor
- Zhejiang Yangli Pharmaceutical Technology Co., Ltd.
Who can join
- Age
- 18 to 75 years
- Sex
- All sexes
- Healthy volunteers
- Not accepted
Inclusion 8
- Minimum age: 18 years
- Maximum age: 75 years
- Study condition: Cancer, Neoplasms, Neoplasms, Breast, Tumor, PARP, Ovarian Neoplasms, Prostatic Cancer, Pancreatic Cancer, Breast Cancer, Biliary Cancer, Colorectal Cancer
- Age ≥ 18 at the time of screening;
- Histological or cytological confirmation of advanced malignancy ;
- Progressive cancer at the time of study entry;
- Adequate organ and marrow function as defined by the protocol;
- Homologous recombination repair gene mutation.
Exclusion 3
- Major surgery within 4 weeks of the first dose of study treatment.
- Spinal cord compression or brain metastases unless asymptomatic, treated and stable and not requiring continuous corticosteroids at a dose of \>10mg prednisone/day or equivalent for at least 4 weeks prior to start of study treatment. Patients with leptomeningeal carcinomatosis are excluded.
- Patients with myelodysplastic syndrome/acute myeloid leukaemia or with features suggestive of myelodysplastic syndrome (MDS)/acute myeloid leukaemia (AML).
Where
1 site, 1 recruiting
Cancer Hospital of Shandong First Medical university
Jinan, Shandong, China
Contact
-
Song Jia Project manager, bachelor
China 86+18503817651 songjia@vybio.com
-
Zhang Nan Assistant project manager, bachelor
China 86+ zhangnan@vybio.com
Potential match only. Final eligibility is determined by the study team.